Clinical study on oncological outocomes of enzalutamide in patients with castration-resistant prostate cancer:multi-institutional, retrospective observational study

Clinical study on oncological outocomes of enzalutamide in patients with castration-resistant prostate cancer:multi-institutional, retrospective observational study - Clinical study of enzalutmide on castration-resistant prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030652

Enrollment

400

Registered

2018-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) castration resistant prostate cancer treated with enzalumide 2) metastatic case

Exclusion criteria

Exclusion criteria: 1) previous abiraterone treatment

Design outcomes

Primary

Measure	Time frame
factors to predict the prognosis (overall survival)	—

Secondary

Measure	Time frame
PSA response rate	—

Countries

Japan

Contacts

Public ContactKazuhiro Suzuki

Gunma University Graduate School of Medicine Department of Urology

kazu@gunma-u.ac.jp027-220-8315

Outcome results